Drug Design Development and Therapy, Год журнала: 2024, Номер Volume 18, С. 1997 - 2020

Опубликована: Июнь 1, 2024

Abstract: The potential anti-cancer effect of traditional Chinese medicine (TCM) monomers has been widely studied due to their advantages well-defined structure, clear therapeutic effects, and easy quality control during the manufacturing process. However, clinical trial information on these is scarce, resulting in a lack knowledge regarding research progress, efficacy, adverse reactions at stage. Therefore, this study systematically reviewed trials TCM registered Clinicaltrials.gov website before 2023.4.30, paying special attention tumors, aiming explore results development prospects field. A total 1982 were started using 69 131 monomers. number performed each year showed an overall upward trend. only 26 entered into 519 interventional anti-tumor trials, with vinblastine (194, 37.38%) camptothecin (146, 28.13%) being most used. 45 tumors lymphoma (112, 21.58%) frequently studied. Clinical are also unevenly distributed across locations sponsors/collaborators. location sponsor/collaborator highest United States (651,32.85%) NIH (77). China its institutions still have large room for progress promoting trials. In next step, priority should be given improvement ability domestic enterprises, universities other institutions, modern scientific technological means solve problems poor water solubility strong toxic side effects monomers, so as promote Keywords: anti-cancer,

Язык: Английский